TVTX

47.0802.53%
WE

William E. Rote

Chief Research Officer

Dr. William E. Rote, also known as Bill, Ph.D., serves as Chief Research Officer at Travere Therapeutics, Inc. He had been Senior Vice President and Head of Research and Development at Travere Therapeutics, Inc. and was its Senior Vice President of Research & Development since February 2017. Dr. Rote served as Head of Research and Development at Retrophin, Inc. until January 2018. Dr. Rote served as Vice President of Corporate Development for New Ventures at Amylin Pharmaceuticals, Inc. from 2007 to 2010 and served as its Vice President, Site Head for Research & Development from September 2012 to July 2014. Dr. Rote has an impressive mix of scientific and operational knowledge, which he has built during an extensive career in the biopharmaceutical industry. Dr. Rote worked at Ardea Biosciences, a wholly owned subsidiary of AstraZeneca, where he served as vice president of clinical development from September 2014 to July 2016. In this role, Dr. Rote was responsible for leading all aspects of clinical trial execution and analysis, including clinical operations, data management and biostatistics. Dr. Rote served as the Chief Operating Officer of Psylin Neurosciences, Inc., a subsidiary of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. Dr. Rote joined Amylin in 2003. Prior to joining Amylin, Dr. Rote held various positions at Corvas International Inc., where, he also served as an Executive Director of Biologics Development from 1993 to 2003 and was responsible for the development of a novel anticoagulant from discovery through Phase II proof-of-concept studies. He served as a Director of Xenome Limited. He received his B.S. in Pre-Medicine and his Ph.D. in Pharmacology from the Pennsylvania State University and received postdoctoral training from the University of Michigan.

Positions